Takeda Expands GeneExpress Subscription, Accesses Complete BioExpress Dataset
Gene Logic Inc. announced that Takeda Chemical Industries, Ltd. ("Takeda"), the largest pharmaceutical company in Japan, has expanded its GeneExpress(R) subscription.
The expanded agreement gives Takeda access to the complete BioExpress(TM) dataset, allowing Takeda researchers to assess the full range of normal and diseased human tissues, animal and cell lines and detailed associated clinical annotations within BioExpress(TM). In addition, Takeda will continue to utilize the complete ToxExpress Predictive System(TM).
Originally, in March 2002, Takeda subscribed to a custom BioExpress(TM) product and the complete ToxExpress(TM) system. Financial details of the multiyear, expanded agreement were not disclosed.
"As a result of this expanded agreement, Takeda and Gene Logic have become more involved partners in working together to advance Takeda's drug discovery and development efforts," said Mark D. Gessler, Chairman, President and CEO of Gene Logic. "We are confident that this larger data set should enable Takeda's researchers to build upon their existing GeneExpress-based discovery efforts, as well as drive new experimentation in novel disease indications. Going forward, we will continue to pursue ways to add value throughout Takeda's global drug discovery and development infrastructure."
This expanded agreement was made in concert with Amersham Biosciences K.K., the Japanese affiliate of Amersham Biosciences and Gene Logic's sales and marketing partner in Japan.
"Our collaboration in Japan with Gene Logic has been very successful. As a leading provider of biotechnology systems, products and services for genomic research, Amersham Biosciences is enthusiastic about facilitating this and future collaborations between Japanese- based pharmaceutical companies and Gene Logic," stated Kazuo Takeuchi, Vice President at Amersham Biosciences K.K. in Tokyo.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.